Allergy Therapeutics (AGY) Competitors GBX 6.40 +0.20 (+3.23%) (As of 12/20/2024 11:48 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines AGY vs. AMYT, APH, BXP, ANCR, EAH, DNL, STX, PXS, CEL, and CHLLShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), Diurnal Group (DNL), Shield Therapeutics (STX), Provexis (PXS), Celadon Pharmaceuticals (CEL), and Chill Brands Group (CHLL). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Amryt Pharma Alliance Pharma Beximco Pharmaceuticals Animalcare Group ECO Animal Health Group Diurnal Group Shield Therapeutics Provexis Celadon Pharmaceuticals Chill Brands Group Allergy Therapeutics (LON:AGY) and Amryt Pharma (LON:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations. Does the media prefer AGY or AMYT? In the previous week, Allergy Therapeutics had 2 more articles in the media than Amryt Pharma. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Allergy Therapeutics' average media sentiment score of 0.37 beat Amryt Pharma's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Allergy Therapeutics Neutral Amryt Pharma Neutral Which has stronger earnings and valuation, AGY or AMYT? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllergy Therapeutics£53.26M5.73-£50.22M-£0.06-106.67Amryt Pharma£210.24M0.00N/A-£33.00N/A Is AGY or AMYT more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -94.29%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allergy Therapeutics-94.29% -155.90% -34.76% Amryt Pharma N/A N/A N/A Does the MarketBeat Community favor AGY or AMYT? Allergy Therapeutics received 118 more outperform votes than Amryt Pharma when rated by MarketBeat users. Likewise, 77.97% of users gave Allergy Therapeutics an outperform vote while only 65.68% of users gave Amryt Pharma an outperform vote. CompanyUnderperformOutperformAllergy TherapeuticsOutperform Votes36177.97% Underperform Votes10222.03% Amryt PharmaOutperform Votes24365.68% Underperform Votes12734.32% SummaryAllergy Therapeutics and Amryt Pharma tied by winning 5 of the 10 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£305.28M£1.17B£5.14B£1.90BDividend Yield8.33%3.04%5.09%5.55%P/E Ratio-106.67131.2390.051,821.81Price / Sales5.731,981.001,117.09386,342.76Price / Cash3.6610.2543.1028.54Price / Book6.403.084.782.78Net Income-£50.22M£152.21M£120.31M£157.16M7 Day Performance3.23%-0.48%-1.92%-2.00%1 Month Performance25.49%-1.88%13.65%21.23%1 Year Performance190.91%98.32%28.34%29.20% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 6.40+3.2%N/A+220.0%£305.28M£53.26M-106.67612Gap UpAMYTAmryt PharmaN/AGBX 143-11.7%N/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma3.2988 of 5 starsGBX 48.40+0.4%GBX 60+24.0%+17.3%£261.64M£183.15M-806.6791,000News CoveragePositive NewsBXPBeximco PharmaceuticalsN/AGBX 36.50flatN/A-14.6%£162.83M£43.08B456.255,500News CoverageANCRAnimalcare GroupN/AGBX 241-0.4%N/A+36.3%£145.49M£76.10M3,023.13220EAHECO Animal Health GroupN/AGBX 68.50-0.7%N/A-37.1%£46.40M£89.42M3,425.00234Gap DownDNLDiurnal GroupN/AGBX 27.30flatN/A+0.0%£46.33M£4.68M-3.2133STXShield TherapeuticsN/AGBX 2.68-2.9%N/A-57.9%£20.92M£21.47M-68.0040,000PXSProvexisN/AGBX 0.63-7.4%N/A+18.2%£14.18M£426,168.0043.754Gap DownCELCeladon PharmaceuticalsN/AGBX 19flatN/A-87.5%£13.08M£11,258.00-236.882,780News CoverageGap DownCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624,187.00-215.007News Coverage Related Companies and Tools Related Companies AMYT Competitors APH Competitors BXP Competitors ANCR Competitors EAH Competitors DNL Competitors STX Competitors PXS Competitors CEL Competitors CHLL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:AGY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGY Stock Alerts